Scientist, Computational Biology
We are seeking a highly-motivated scientist for tasks including analysis of large and small public transcriptomic data sets, development and implementation of bioinformatic algorithms, and interpretation of omic data from various sources in the context of identifying and validating targets in ImmunoOncology. Projects include target discovery and validation, mechanism-of-action elucidation, toxicity prediction, and biomarker identification.
Project team participation will be expected as well as the ability to lead colleagues in asking and answering computational biology questions. You will work independently on a wide variety of tasks and collaborates with scientists at all levels and disciplines. As a key member of a small Computational Biology team, you will have the opportunity to be involved in projects from Discovery through to the clinic.
EDUCATION, EXPERIENCE AND SKILLS REQUIREMENTS:
Ph.D. in bioinformatics, genomics, immunology, cancer biology, or a related discipline. 2+ years postdoc preferred.
Experience working with large genomic data sets, planning Next Generation Sequencing experiments and analyses, and applying machine learning algorithms including classification and regression models.
Comfort with working in a Unix-type environment and programming in languages such as R, python, and perl.
Excellent written and oral communciation skills are expected
A strong background in biology is important, with experience in immunology or oncology a plus.
About FLX Bio
FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio's small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment. Its lead candidate FLX475, a best-in-class CCR4 inhibitor, entered Phase 1 studies in December 2017 and has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers. The company employs a precision medicine strategy for prospective patient selection in clinical studies, applying its robust computational and translational biology capabilities to identify key biomarkers that should maximize clinical response and increase the probability of clinical success. In addition, FLX is developing small molecule inhibitors of GCN2, a stress response kinase that detects amino acid starvation in the tumor microenvironment, and USP7, a therapeutic target involved in multiple cancer pathways.
Located in South San Francisco, Calif., and funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.